# US 2025/0154237 A1 · Fully human monoclonal antibodies against human progranulin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154237 A1
- Document ID: US20250154237A1
- Status: Published application
- Kind: A1
- Application number: 18/838,875
- Filed: 2023-02-23
- Published: 2025-05-15
- Earliest claimed: 2022-02-24
- Applicants: A & G Pharmaceutical, Inc.
- Inventors: Ginette Serrero
- Web page: https://patentgrep.com/patent/US20250154237A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61P 35/00: Antineoplastic agents
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- G01N 33/57575: {involving oncogenic proteins}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described herein are antibodies, particularly monoclonal antibodies, that specifically bind to human progranulin and are useful for the treatment of cancer in patients. Methods for preparing and using the same are also provided.

## Claims

### Claim at position 1

1-33. (canceled)

### Claim 34

An isolated antibody or antigen binding fragment thereof, comprising:
a) a heavy chain variable (VH) region comprising the CDR sequences SEQ ID NOs: 1, 2, and 3 and a light chain variable (VL) region comprising CDR sequences SEQ ID NOs: 4, 5, and 6, respectively;
b) a heavy chain variable (VH) region comprising the CDR sequences SEQ ID NOs: 7, 8, and 9 and a light chain variable region comprising CDR sequences SEQ ID NOs: 10, 11 and 12, respectively;
c) a heavy chain variable (VH) region comprising the CDR sequences SEQ ID NOs: 13, 14, and 15 and a light chain variable (VL) region comprising CDR sequences SEQ ID NOs: 16, 17, and 18, respectively;
d) a heavy chain variable (VH) region comprising the CDR sequences SEQ ID NOs: 19, 20, 21 and a light chain variable (VL) region comprising CDR sequences SEQ ID NOs: 22, 23, and 24, respectively;
e) the heavy chain variable (VH) and light chain variable (VL) regions comprising the CDR sequences SEQ ID NOS. 1-3 and 7-9, respectively;
f) the heavy chain variable (VH) and light chain variable (VL) regions comprising the CDR sequences SEQ ID NOS. 4-6 and 10-12, respectively;
g) the heavy chain variable (VH) and light chain variable (VL) regions comprising SEQ ID NO. 13 and SEQ ID NO. 14, respectively;
h) the heavy chain variable (VH) and light chain variable (VL) regions comprising the CDR sequences SEQ ID NOS. 15-17 and 21-23, respectively;
i) the heavy chain variable (VH) and light chain variable (VL) regions comprising the CDR sequences SEQ ID NOS. 18-20 and 24-26, respectively;
j) the heavy chain variable (VH) and light chain variable (VL) regions comprising SEQ ID NO. 27 and SEQ ID NO. 28, respectively;
k) the heavy chain variable (VH) and light chain variable (VL) regions comprising the CDR sequences SEQ ID NOS. 29-31 and 35-37, respectively;
l) the heavy chain variable (VH) and light chain variable (VL) regions comprising the CDR sequences SEQ ID NOS. 32-34 and 38-40, respectively;
m) the heavy chain variable (VH) and light chain variable (VL) regions comprising SEQ ID NO. 41 and SEQ ID NO. 42, respectively;
n) the heavy chain variable (VH) and light chain variable (VL) regions comprising the CDR sequences SEQ ID NOS. 43-45 and 49-51, respectively;
o) the heavy chain variable (VH) and light chain variable (VL) regions comprising the CDR sequences SEQ ID NOS. 46-48 and 52-54, respectively;
p) the heavy chain variable (VH) and light chain variable (VL) regions comprising SEQ ID NO. 55 and SEQ ID NO. 56, respectively;
or a derivative of any one of a)-p);
wherein the antibody or antigen binding fragment thereof specifically binds to human progranulin (PGRN).

### Claim 35 (depends on 34)

The isolated antibody or antigen binding fragment thereof of claim 34, comprising:
a) a heavy chain variable (VH) region comprising SEQ ID NO: 25 and a light chain variable (VL) region comprising SEQ ID NO:27;
b) a heavy chain variable (VH) region comprising SEQ ID NO: 29 and a light chain variable (VL) region comprising SEQ ID NO:31;
c) a heavy chain variable (VH) region comprising SEQ ID NO: 33 and a light chain variable (VL) region comprising SEQ ID NO:35; or
d) a heavy chain variable (VH) region comprising SEQ ID NO: 37 and a light chain variable (VL) region comprising SEQ ID NO:39.

### Claim 36 (depends on 34)

An antibody of claim 34 wherein the antibody is internalized into a cell that expresses hu PGRN in vitro and/or in vivo.

### Claim 37 (depends on 34)

An antibody of claim 34 that competes with trastuzumab for binding to hu PGRN receptor on the cell.

### Claim 38 (depends on 34)

The antibody of claim 34 selected from the group consisting of antibodies 10C8, 16C11, 14A6, and 10B3.

### Claim 39 (depends on 34)

An antibody of claim 34 that does not compete with trastuzumab for binding to hu PGRN receptor on the cell.

### Claim 40 (depends on 39)

The antibody of claim 39 selected from the group consisting of antibodies 10C8, 16C11, 14A6, and 10B3.

### Claim 41 (depends on 34)

A combination of antibodies of claim 34, wherein at least one antibody competes with trastuzumab for binding to hu PGRN receptor on the cell and at least one antibody does not compete with trastuzumab for binding to hu PGRN receptor on the cell.

### Claim 42 (depends on 34)

The antibody of claim 34 that is an isolated monoclonal antibody.

### Claim 43 (depends on 42)

The antibody of claim 42 wherein the monoclonal antibody is a human monoclonal antibody.

### Claim 44 (depends on 34)

The antibody of claim 34 wherein said antibody is derived from a human antibody, human IgG, human IgG1, human IgG2, human IgG2a, human IgG2b, human IgG3, human IgG4, human IgM, human IgA, human IgA1, human IgA2, human IgD, human IgE, canine antibody, canine IgGA, canine IgGB, canine IgGC, canine IgGD, chicken antibody, chicken IgA, chicken IgD, chicken IgE, chicken IgG, chicken IgM, chicken IgY, goat antibody, goat IgG, mouse antibody, mouse IgG, pig antibody, rat antibody, Ilaman antibody, alpacan antibody, shark antibody and a camel antibody.

### Claim 45 (depends on 34)

A derivative of claim 34, optionally selected from the group consisting of an Fab, Fab2, Fab′ single chain antibody, Fv, single chain, mono-specific antibody, bispecific antibody, trimeric antibody, multi-specific antibody, multivalent antibody, chimeric antibody, canine-human chimeric antibody, canine-mouse chimeric antibody, antibody comprising a canine Fc, humanized antibody, human antibody, caninized antibody, CDR-grafted antibody, shark antibody, and a nanobody.

### Claim 46 (depends on 34)

A derivative of claim 34 comprising a detectable label fixably attached thereto, optionally wherein the detectable label is selected from the group consisting of fluorescein, DyLight, Cy3, Cy5, FITC, HiLyte Fluor 555, HiLyte Fluor 647, 5-carboxy-2,7-dichlorofluorescein, 5-carboxyfluorescein, 5-FAM, hydroxy tryptamine, 5-hydroxy tryptamine (5-HAT), 6-carboxyfluorescein (6-FAM), FITC, 6-carboxy-1,4-dichloro-2′,7′-dichlorofluorescein (TET), 6-carboxy-1,4-dichloro-2′,4′,5′,7′-tetrachlorofluorescein (HEX), 6-carboxy-4′,5′-dichloro-2′,7′-dimethoxyfluorescein (6-JOE), an Alexa fluor, Alexa fluor 350, Alexa fluor 405, Alexa fluor 430, Alexa fluor 488, Alexa fluor 500, Alexa fluor 514, Alexa fluor 532, Alexa fluor 546, Alexa fluor 555, Alexa fluor 568, Alexa fluor 594, Alexa fluor 610, Alexa fluor 633, Alexa fluor 635, Alexa fluor 647, Alexa fluor 660, Alexa fluor 680, Alexa fluor 700, Alexa fluor 750, a BODIPY fluorophores, BODIPY 492/515, BODIPY 493/503, BODIPY 500/510, BODIPY 505/515, BODIPY 530/550, BODIPY 542/563, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY 630/650-X, BODIPY 650/665-X, BODIPY 665/676, FL, FL ATP, FI-Ceramide, R6G SE, TMR, TMR-X conjugate, TMR-X, SE, TR, TR ATP, TR-X SE, a rhodamine, rhodamine 110, rhodamine 123, rhodamine B, rhodamine B 200, rhodamine BB, rhodamine BG, rhodamine B extra, 5-carboxytetramethylrhodamine (5-TAMRA), 5 GLD, 6-carboxyrhodamine 6G, Lissamine, Lissamine Rhodamine B, Phallicidine, Phalloidine, rhodamine red, Rhod-2, 6-carboxy-X-rhodamine (ROX), carboxy-X-rhodamine (5-ROX), Sulphorhodamine B can C, Sulphorhodamine G Extra, 6-carboxytetramethyirhodamine (TAMRA), tetramethylrhodamine (TRITC), rhodamine WT, Texas Red, and Texas Red-X.

### Claim 47 (depends on 34)

The antibody of claim 34 comprising an effector moiety attached thereto, optionally wherein the effector moiety is selected from the group consisting of a cytotoxic drug, toxin, diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin, and radiochemical.

### Claim 48 (depends on 47)

The antibody of claim 47 further comprising a cleavable linker positioned between the antibody and the effector moiety, wherein said cleavable linker releases the effector moiety into or within a cell.

### Claim 49 (depends on 34)

An isolated polynucleotide encoding antibody or derivative of claim 34, optionally wherein a nucleic acid sequence of at least one of SEQ ID NOS. 57-64.

### Claim 50 (depends on 49)

An expression vector comprising one or more polynucleotides of claim 49.

### Claim 51 (depends on 49)

A host cell comprising the isolated polynucleotide of claim 49.

### Claim 52 (depends on 34)

A composition comprising at least one antibody or derivative of claim 34; and, a pharmaceutically acceptable carrier.

### Claim 53 (depends on 49)

A composition comprising at least one isolated polynucleotide of claim 49; and, a pharmaceutically acceptable carrier.

### Claim 54 (depends on 34)

A method for detecting hu PGRN on a cell, the method comprising contacting a test biological sample with an antibody or derivative of claim 34 and detecting the antibody bound to the biological sample or component thereof, optionally wherein:
the test biological sample comprises mammalian cells, tissue(s), and/or blood; and/or,
the method is an in vivo method or an in vitro method.

### Claim 55 (depends on 54)

The method of claim 54 wherein the cell is selected from the group consisting of a breast cancer, adenocarcinoma epidermal growth factor receptor (EGF-R) breast cancer, basal breast carcinoma, estrogen receptor (ER) luminal breast cancer, ER positive tamoxifen resistant luminal breast cancer, letrozole resistant luminal breast cancer, biliary cancer, bladder cancer, brain cancer, glioblastoma, colorectal cancer, epidermoid carcinoma, squamous carcinoma, esophogeal cancer, gastric cancer, hepatocellular cancer, kidney/renal cancer, laryngeal cancer, lung cancer, non-small-cell lung carcinoma, lung adenocarcinoma, mesothelioma, myeloma/leukemia, ovarian cancer, prostate cancer, and uterine cancer cell.

### Claim 56 (depends on 54)

The method of claim 54, further comprising comparing the amount of binding to the test biological sample or components thereof to the amount of binding to a control biological sample or components thereof, wherein increased binding to the test biological sample or components thereof relative to the control biological sample or components thereof indicates the presence of a cell expressing hu PGRN in the test biological sample.

### Claim 57 (depends on 34)

A method for treating, preventing and/or ameliorating cancer in a mammal comprising administering to the mammal at least one effective dose of a pharmaceutical composition comprising an antibody or derivative of claim 34, optionally wherein:
the antibody or derivative is administered as a drug conjugate;
the antibody or derivative is administered to the mammal in a dosage amount of about 1 to 50 mg/kg; and/or,
multiple doses of the composition are administered to the mammal.

### Claim 58 (depends on 57)

The method of claim 57 wherein the cancer is selected from the group consisting of breast cancer, adenocarcinoma epidermal growth factor receptor (EGF-R) breast cancer, basal breast carcinoma, estrogen receptor (ER) luminal breast cancer, ER positive tamoxifen resistant luminal breast cancer, letrozole resistant luminal breast cancer, biliary cancer, bladder cancer, brain cancer, glioblastoma, colorectal cancer, epidermoid carcinoma, squamous carcinoma, esophogeal cancer, gastric cancer, hepatocellular cancer, kidney/renal cancer, laryngeal cancer, lung cancer, non-small-cell lung carcinoma, lung adenocarcinoma, mesothelioma, myeloma/leukemia, ovarian cancer, prostate cancer, and uterine cancer.

### Claim 59 (depends on 57)

The method of claim 57 wherein the drug conjugate comprises a cytotoxic effector moiety, optionally wherein the effector moiety is selected from the group consisting of a cytotoxic drug, toxin, diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin, and radiochemical.

### Claim 60 (depends on 59)

The method of claim 59 wherein the drug conjugate comprises a cleavable linker positioned between the antibody or derivative and the effector moiety, wherein said cleavable linker releases the effector moiety into or within a cell.

### Claim 61 (depends on 34)

A kit for detecting the expression of hu PGRN in or on a cell, the kit comprising an antibody or derivative of claim 34 and instructions for use, optionally wherein the antibody or derivative is in lyophilized form.

### Claim 62 (depends on 61)

The kit of claim 61 wherein the cell is selected from the group consisting of a breast cancer, adenocarcinoma epidermal growth factor receptor (EGF-R) breast cancer, basal breast carcinoma, estrogen receptor (ER) luminal breast cancer, ER positive tamoxifen resistant luminal breast cancer, letrozole resistant luminal breast cancer, biliary cancer, bladder cancer, brain cancer, glioblastoma, colorectal cancer, epidermoid carcinoma, squamous carcinoma, esophogeal cancer, gastric cancer, hepatocellular cancer, kidney/renal cancer, laryngeal cancer, lung cancer, non-small-cell lung carcinoma, lung adenocarcinoma, mesothelioma, myeloma/leukemia, ovarian cancer, prostate cancer, and uterine cancer cell.
